title: Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.
abstract: Opinion statementOver the past 15 years, the landscape of Ph+ ALL has changed dramatically. No longer the most dreaded form of acute leukemia, the advent of tyrosine kinase inhibitors (TKIs) has ushered in a new era, as TKIs have become the backbone of any treatment regimen for Ph+ ALL. A greater number achieve a complete remission allowing for more patients to get the transplant, although probably less patients need a transplant. For the first time in decades, there is hope for older patients with Ph+ ALL. Defining residual disease at an increasingly lower level of disease burdens termed minimal residual disease (MRD) has allowed treatment algorithms to be designed based on deep molecular responses. The aggregate of recent data suggest that this is the most important endpoint to predict for long-term outcome and to decide on the optimal post-remission approach, including transplant. Novel agents, such as blinatumumab, are likely to be incorporated into therapy for relapse and as initial therapy in an attempt to increase the number of patients who may have deep molecular responses. Many more patients with Ph+ ALL are long-term survivors, and the future is looking brighter for this group of patients.
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bait St., P.O.B. 3235, 9103102, Jerusalem, IL, Israel. ronsonaaron@szmc.org.il.
authors.forename: Aaron
authors.initials: A
authors.lastname: Ronson
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bait St., P.O.B. 3235, 9103102, Jerusalem, IL, Israel.
authors.forename: Ariella
authors.initials: A
authors.lastname: Tvito
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bait St., P.O.B. 3235, 9103102, Jerusalem, IL, Israel.|Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.|Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
mesh_terms: D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D055808:Drug Discovery; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D018365:Neoplasm, Residual / Q000473:pathology; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
keywords: Minimal residual disease; Ph-like ALL; Ph-positive ALL; Tyrosine kinase inhibitors